The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis

被引:17
作者
Antczak, Carina [1 ]
Trinh, Vincent Q. [1 ]
Sood, Akshay [3 ,5 ,6 ]
Ravi, Praful [3 ]
Roghmann, Florian [1 ,4 ]
Trudeau, Vincent [1 ]
Chang, Steven L. [5 ,6 ]
Karakiewicz, Pierre I. [1 ]
Kibel, Adam S. [5 ,6 ]
Krishna, Nandita [5 ,6 ]
Nguyen, Paul L. [7 ]
Saad, Fred [2 ]
Sammon, Jesse D. [3 ]
Sukumar, Shyam [8 ]
Zorn, Kevin C. [1 ]
Sun, Maxine [1 ]
Trinh, Quoc-Dien [5 ,6 ]
机构
[1] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[2] Univ Montreal, Ctr Hlth, Div Urol, Montreal, PQ, Canada
[3] Vattikuti Urol Inst, Henry Ford Hlth Syst, Detroit, MI USA
[4] Ruhr Univ Bochum, Marienhosp, Dept Urol, Herne, Germany
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Div Urol Surg, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Ctr Surg & Publ Hlth, Boston, MA 02115 USA
[7] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Radiat Oncol, Boston, MA 02115 USA
[8] Univ Minnesota, Dept Urol, Minneapolis, MN USA
关键词
kidney; carcinoma; renal cell; bone and bones; neoplasm metastasis; hospital charges; ZOLEDRONIC ACID; PROSTATE-CANCER; UNITED-STATES; SURVIVAL; COMPLICATIONS; SECONDARY; PATTERNS; THERAPY; DISEASE;
D O I
10.1016/j.juro.2013.12.042
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We examined temporal trends in skeletal related events and associated charges in patients with renal cell carcinoma metastatic to bone. We also identified patient and hospital characteristics associated with skeletal related events and related mortality. Materials and Methods: Using the Nationwide Inpatient Sample we abstracted data on patients with renal cell carcinoma who were diagnosed with concomitant bone metastasis between 1998 and 2010. Patients who experienced a skeletal related event were identified and hospital charges were calculated. Multivariate regression models fitted with generalized estimating equations were used to examine predictors of skeletal related events and related in-hospital mortality. Results: Between 1998 and 2010 a weighted estimate of 144,889 renal cell carcinoma hospital visits of patients with bone metastasis was identified in the Nationwide Inpatient Sample, of which 20.8% involved a skeletal related event. In these cases from 1998 to 2010 the inflation adjusted mean yearly costs associated with hospital admission increased by 207% in 2013 United States dollars (estimated annual percent change 8.94%, p < 0.001). Conversely, the rates of skeletal related events and skeletal related event associated mortality decreased significantly (estimated annual percent change -1.11% and -2.9%, respectively, each p < 0.001). Conclusions: The prevalence and in-hospital mortality of skeletal related event associated hospitalization for metastatic renal cell carcinoma is decreasing but such charges to health care in the United States are increasing at an alarming rate. These findings highlight the need for cost-effective treatment strategies to prevent or treat these morbid complications.
引用
收藏
页码:1678 / 1684
页数:7
相关论文
共 20 条
[1]  
[Anonymous], 2012, World Health Statistics 2012
[2]   Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom [J].
Botteman, M. F. ;
Meijboom, M. ;
Foley, I. ;
Stephens, J. M. ;
Chen, Y. M. ;
Kaura, S. .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2011, 12 (06) :575-588
[3]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[4]   Imaging in metastatic renal cell carcinoma [J].
Griffin, Nyree ;
Gore, Martin E. ;
Sohaib, S. Aslam .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 189 (02) :360-370
[5]   Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases [J].
Hagiwara, M. ;
Delea, T. E. ;
Saville, M. W. ;
Chung, K. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2013, 16 (01) :23-27
[6]   Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma [J].
Henry, David H. ;
Costa, Luis ;
Goldwasser, Francois ;
Hirsh, Vera ;
Hungria, Vania ;
Prausova, Jana ;
Scagliotti, Giorgio Vittorio ;
Sleeboom, Harm ;
Spencer, Andrew ;
Vadhan-Raj, Saroj ;
von Moos, Roger ;
Willenbacher, Wolfgang ;
Woll, Penella J. ;
Wang, Jianming ;
Jiang, Qi ;
Jun, Susie ;
Dansey, Roger ;
Yeh, Howard .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) :1125-1132
[7]   Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma [J].
Lipton, A ;
Zheng, M ;
Seaman, J .
CANCER, 2003, 98 (05) :962-969
[8]   Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group [J].
Manola, Judith ;
Royston, Patrick ;
Elson, Paul ;
McCormack, Jennifer Bacik ;
Mazumdar, Madhu ;
Negrier, Sylvie ;
Escudier, Bernard ;
Eisen, Tim ;
Dutcher, Janice ;
Atkins, Michael ;
Heng, Daniel Y. C. ;
Choueiri, Toni K. ;
Motzer, Robert ;
Bukowski, Ronald .
CLINICAL CANCER RESEARCH, 2011, 17 (16) :5443-5450
[9]   Patterns of bisphosphonate use in the united states in the treatment of metastatic bone disease [J].
Mortimer, Joanne E. ;
Schulman, Kathy ;
Kohles, Joseph D. .
CLINICAL BREAST CANCER, 2007, 7 (09) :682-689
[10]   Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers [J].
Saad, F ;
Lipton, A .
BJU INTERNATIONAL, 2005, 96 (07) :964-969